Infrared Photobiomodulation in Humans With Epilepsy
An Open Label Pilot Study of Infrared Photobiomodulation in Humans With Epilepsy
Beth Israel Deaconess Medical Center
13 participants
Nov 25, 2025
INTERVENTIONAL
Conditions
Summary
Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.
Eligibility
Inclusion Criteria4
- Drug resistant epilepsy
- Age 18 or older
- Average seizure rate of at least 2 seizures per month
- Accurate seizure diary with at least 3 months recorded
Exclusion Criteria5
- Implanted intracranial neurostimulation device (DBS or RNS)
- Intracranial shunt
- Skin photosensitivity
- Cancer on scalp
- Taking any medication that can cause photosensitivity
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
a hat with infrared lights will be worn for 30 minutes daily for 6 months
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07145489